Artificial endolysine-ArtE2 and related biological material, preparation method, preparation and application thereof

By transforming natural endolin, artificial endolin-ArtE2 is designed to solve the problem that natural endolin is difficult to pass through the outer membrane and instability of Gram-negative bacteria, and it is effective for Gram-positive and negative bacteria. Antibacterial, provides stable antibiotic alternatives, with wide application prospects.

CN118910019APending Publication Date: 2024-11-08YOTA BIO-ENG CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411250818.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Natural endolins are difficult to pass through the outer membrane of Gram-negative bacteria and are unstable when used, and cannot effectively fight Gram-positive and negative bacteria.

Method used

By modifying natural endolins, artificial endolins-ArtE2 is designed, whose amino acid sequence is optimized to increase biological activity and substrate specificity, and can pass through the outer membrane and lyse the pathogenic cell walls without an external permeabilizer. , prepared by DNA recombination technology and chemical synthesis methods to form a preparation with antibacterial effect.

Benefits of technology

Artificial endolin-ArtE2 has obvious antibacterial effects on Gram-positive and negative bacteria, which improves the sensitivity to Gram-negative bacteria, and has a broad range of fields such as food safety, pathogen detection, disinfection and vaccine development. Application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910019A_ABST
    Figure CN118910019A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of genetic engineering, in particular to an artificial endolysin-ArtE2 and a related biological material, a preparation method, a preparation and application thereof. The amino acid sequence of the artificial endolysine-ArtE2 is a) a sequence as shown in a sequence 1, or b) a sequence which is obtained by deleting, substituting or adding one or more amino acid residues to the sequence as shown in the sequence 1 and retains the characteristic of controlling pathogenic bacteria infection, or c) a sequence as shown in a sequence as shown in the sequence 1. C) a sequence which has the homology of more than 60% with the amino acid sequence shown in the sequence 1 and retains the characteristic of controlling pathogenic bacteria infection. Natural endolysin molecules are modified to obtain the artificial endolysin-ArtE2, the artificial endolysin-ArtE2 can penetrate through an outer membrane and crack cell walls of pathogenic bacteria in the absence of an external permeabilizing agent, and the artificial endolysin-ArtE2 has an obvious antibacterial effect on gram-positive bacteria and gram-negative bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of genetic engineering technology, and in particular to an artificial endolysin-ArtE2 and related biological materials, preparation methods, preparations and applications thereof. Background Art

[0002] Drug resistance in pathogenic bacteria is a major public health issue. Multidrug-resistant bacteria, especially those resistant to cephalosporins and carbapenems, are a major monitoring indicator in clinical microbiology. To address this problem, researchers and pharmaceutical companies have spared no effort in the research and industrialization of new antimicrobial agents.

[0003] Endolysin is an enzyme expressed by the phage genome and is an important substance for lysing bacteria in the phage infection host cycle. With the help of a membrane protein-choline, holes are formed on the inner membrane, allowing endolysin to enter the cell and cut the peptidoglycan bond, causing bacterial lysis and starting a new infection cycle. Endolysin is a globular or multi-subunit protein that was originally discovered in phages that infect Gram-negative bacteria and contains only one catalytic domain that catalyzes the degradation of peptidoglycan. Multi-subunit endolysin is found in Gram-positive bacteria and has two domains: a cell wall binding domain and a catalytic domain.

[0004] Endolysins only act on peptidoglycan and will not cause bacterial mutation or drug resistance, which makes them more promising than traditional antibiotics. Endolysins are effective alternatives to antibiotics due to their unique mechanism, transient cell wall effect, non-toxicity, non-immunogenicity and biodegradability, and their synergistic effect with traditional antibiotics effectively reduces their usage.

[0005] Gram-positive bacteria are more susceptible to lytic enzymes due to their exposed peptidoglycan layer. Gram-negative bacteria have an outer membrane protecting the cell wall, which is composed of a hydrophilic outer surface of lipopolysaccharide and a hydrophobic inner surface that only allows molecules smaller than 600 Da to pass through, and can act as a selective barrier to prevent the passage of antimicrobial compounds. Therefore, the outer membrane is the main resistance mechanism of Gram-negative bacteria, making them insensitive to hydrophobic substances and large hydrophilic compounds such as endolysins.

[0006] At the same time, both natural and synthetic cationic polypeptides can be fused with natural endolysins, so natural endolysins still have certain instability when used. Summary of the invention

[0007] In view of the technical problem that natural endolysins are not easy to pass through the outer membrane of Gram-negative bacteria and are unstable during use, the present invention provides an artificial endolysin-ArtE2 and its related biomaterials, preparation methods, preparations and applications. By modifying the natural endolysin molecules, artificial endolysin-ArtE2 is obtained, which can pass through the outer membrane and lyse the cell wall of pathogens without an external permeabilizing agent, and has a significant antibacterial effect on both Gram-positive and Gram-negative bacteria.

[0008] In a first aspect, the present invention provides an artificial endolysin-ArtE2, whose amino acid sequence is: a) a sequence as shown in sequence 1, or, b) a sequence obtained by deleting, replacing or adding one or more amino acid residues of the sequence shown in SEQ ID NO: 1 and retaining the property of controlling pathogenic bacteria infection, or, c) A sequence that has a homology of more than 60% with the amino acid sequence shown in SEQ ID NO: 1 and retains the ability to control pathogenic bacteria infection.

[0009] In the second aspect, the present invention provides a method for preparing an artificial endolysin-ArtE2. Artificial endolysin-ArtE2 can be obtained by recombinant means or chemical synthesis. Preferably, artificial endolysin-ArtE2 is expressed in different hosts by DNA recombination technology and obtained by purification, that is, a host containing a nucleic acid molecule encoding artificial endolysin-ArtE2 or a recombinant expression vector thereof is cultured and secreted, so that artificial endolysin-ArtE2 is secreted in the supernatant of the fermentation broth, and then purified to obtain the polypeptide. The purification method can be achieved using enzyme-linked immunosorbent assay, chromatography, cell precipitation and / or other known processes.

[0010] In a third aspect, the present invention provides an artificial endolysin-ArtE2 related biomaterial, comprising a combination of one or more of the following biomaterials: (1) A nucleic acid molecule encoding an artificial endolysin-ArtE2; (2) a recombinant expression vector containing the nucleic acid molecule described in (1); (3) a host containing the nucleic acid molecule described in (1); (4) A host containing the recombinant expression vector described in (2).

[0011] Furthermore, the starting vector of the recombinant expression vector in (2) is pCold I vector.

[0012] Furthermore, the host in (3) or (4) is a bacterium (such as Escherichia coli, Lactococcus lactis, etc.), a yeast (such as Pichia pastoris, Saccharomyces cerevisiae, Yarrowia lipolytica, etc.), a mammalian cell (such as CHO cell, etc.) or a plant cell.

[0013] In a fourth aspect, the present invention provides a preparation containing artificial endolysin-ArtE2 or its related biological materials; preferably, the preparation also contains food, pesticides, feed, detergents and / or other ingredients permitted in the pharmaceutical field.

[0014] Furthermore, the dosage form of the preparation is selected from gel, granules, emulsion, liniment, spray, tablet, suppository, injection, tincture, capsule, cream.

[0015] In a fifth aspect, the present invention provides an artificial endolysin-ArtE2, and its related biological materials or preparations for pharmaceutical use, wherein the drug is selected from the following: Ⅰ. Drugs that inhibit bacteria; Ⅱ. Drugs for preventing and / or treating diseases caused by bacterial infections; Wherein, the bacteria are Gram-positive bacteria or Gram-negative bacteria, preferably Staphylococcus aureus or Escherichia coli; Diseases caused by bacterial infections include mastitis, dermatitis, sepsis, food poisoning, pneumonia, osteomyelitis, impetigo, bacteremia, endocarditis, and enteritis caused by chronic bacterial-induced biofilms.

[0016] The beneficial effects of the present invention are: The artificial endolysin-ArtE2 provided by the present invention can penetrate the outer membrane and lyse the cell wall of pathogens in the absence of an external permeabilizing agent, and has obvious antibacterial effects on both Gram-positive and Gram-negative bacteria. It has broad application prospects in the fields of food safety, pathogen detection, disinfection, nanotechnology and vaccine development. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0018] Figure 1 Schematic diagram of the 3D structure of the catalytic domain of the artificial endolysin ArtE2 with N-acetylmuramoyl-L-alanine amidase activity.

[0019] Figure 2 This is a schematic diagram of the specific action sites of artificial endolysin-ArtE2 and peptidoglycan structure predicted by PyMOL 2.5.5.

[0020] Figure 3 It is a bar graph comparing the biological activities of natural endolysin-2 and artificial endolysin-ArtE2 against Staphylococcus aureus.

[0021] Figure 4 This is the SDS-PAGE electrophoresis pattern of artificial endolysin-ArtE2.

[0022] Figure 5 These are photos and curve graphs showing the effects of different concentrations of artificial endolysin-ArtE2 on Escherichia coli.

[0023] Figure 6 These are photos and line graphs showing the effects of artificial endolysin-ArtE2 on Escherichia coli over time.

[0024] Figure 7 These are photos and curve graphs showing the effects of different concentrations of artificial endolysin-ArtE2 on Staphylococcus aureus.

[0025] Figure 8 These are photos and line graphs showing the effect of artificial endolysin-ArtE2 on Staphylococcus aureus over time.

[0026] Fig. 9 These are comparison photos of the fingers of a patient with Staphylococcus aureus bacterial infection before and two weeks after application of the artificial endolysin-ArtE2 gel preparation. DETAILED DESCRIPTION

[0027] In order to enable those skilled in the art to better understand the technical solutions in the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.

[0028] Example 1 Computer analysis and inhibition zone test of artificial endolysin-ArtE2 Extraction of endophytic bacteria Bacillus arguta Bacillus aryabhattai ) DNA was obtained from the human embryonic ovary tract and the gene encoding natural endolysin-2 was identified and isolated using DNA sequencing data. The protein sequence of natural endolysin-2 is shown in Sequence 2, and the corresponding nucleotide sequence is shown in Sequence 3. The natural endolysin-2 protein sequence was optimized using a computer simulation protein design tool (Rosetta design) to obtain artificial endolysin-ArtE2. This strategy focuses on modifying specific amino acids to increase the biological activity and substrate specificity of the enzyme. The specific optimization method is to use histidine and threonine to replace tyrosine and arginine at positions 167 and 169, respectively. In addition, a cationic polypeptide (sequence KRKKRKKRK) was added after methionine at position 1 to promote activity against Gram-negative bacteria. The amino acid sequence of the obtained artificial endolysin-ArtE2 is shown in Sequence 1.

[0029] The 3D structure of artificial endolysin-ArtE2 was predicted using the RCSB PDB and UniProt databases. The CD search tool (Conserved Domain Search Service) on the National Center for Biotechnology Information (NCBI) server was used to identify functional domains in protein sequences, and the catalytic domain of artificial endolysin-ArtE2 with N-acetylmuramoyl-L-alanine amidase activity was characterized. The molecular docking of artificial endolysin-ArtE2 with peptidoglycan was completed using PyMOL software version 2.5.5. Before the docking operation, the protein and peptidoglycan structures were predicted. During the minimization process, only the torsion angles in the amino acid side chains were modified, and other properties, including bond lengths and main chain atomic positions, were maintained. PyMOL software version 2.5.5 visualized the three-dimensional structure of artificial endolysin-ArtE2 and its interaction sites with ligands. About 20 chimeric artificial endolysin-ArtE2 variants with clear regions, including engineered artificial endolysin-ArtE2, were obtained. The domain of artificial endolysin-ArtE2 was analyzed by sequence analysis, and the most active artificial endolysin-ArtE2 was obtained. Threonine interacts with histidine spatially through hydrogen bonds. Histidine is an important site for amidase activity and directly interacts with alanine residues in peptidoglycan. Figure 2 Circles indicate involved residues in peptidoglycan and dashed lines indicate polar interactions.

[0030] The biological activities of natural endolysin-2 and artificial endolysin-ArtE2 were tested using Staphylococcus aureus. Staphylococcus aureus was cultured in LB liquid medium for 24 hours to obtain a concentration of 10 8 CFU / mL. Use LB plate culture medium to pour sterile plates, inoculate Staphylococcus aureus culture solution, and solidify for 3 hours. Use a stainless steel puncher with an outer diameter of 7mm to punch four holes on each plate, add the same volume (100μL) of natural endolysin-2, artificial endolysin-ArtE2 or negative control to the wells, place the plate at 37°C and culture for 24 hours, and then measure the diameter of the inhibition zone. Set up three replicates. Compared with natural endolysin-2, the artificial endolysin-ArtE2 designed by the present invention has histidine and threonine concentrated in the catalytic domain, and its activity is significantly increased, which has a higher inhibitory effect on pathogens such as Staphylococcus aureus ( Figure 3 ).

[0031] Example 2 Recombinant expression and purification of artificial endolysin-ArtE2 The artificial endolysin-ArtE2 gene was cloned according to the standard DNA cloning technique of Sambrook, Maniatis et al. (1989). The artificial endolysin-ArtE2 gene was inserted into the pCold I vector to construct a recombinant plasmid. Positive transformants were screened on LB agar supplemented with 100 μg / mL ampicillin. The constructed plasmid pCold I-artificial endolysin-ArtE2 was transformed into competent Escherichia coli BL21 (DE3) for expression. All cloned fragments were verified by sequencing analysis. The exponentially growing cells (OD 600 =0.6), and then the artificial endolysin-ArtE2 was recombinantly expressed. After that, the cells were centrifuged at 3900g for 30 minutes at 4°C, and the obtained cell pellet was resuspended in 1 / 25 volume of lysis buffer (20mM NaH2PO4 / NaOH, 0.5M NaCl, pH7.4).

[0032] The cell lysate was subjected to three freeze-thaw cycles (80°C / 22°C) and then to 8 cycles of sonication, 30 seconds of pulse, 30 seconds of rest, and 40% amplitude. A wash buffer of 50 to 80 mM low protein-dependent imidazole was used during purification to achieve higher purification selectivity. After dialysis, the protein concentration was determined spectrophotometrically using a silica cuvette at a wavelength of 280 nm. The expression of the target gene was induced by adding 0.5 mM IPTG, and then the cells were lysed, centrifuged, and the supernatant was purified by Ni-NTA to obtain the artificial endolysin-ArtE2. Figure 4 Shown is the protein electrophoresis spectrum of artificial endolysin-ArtE2 (about 29KDa). From left to right, the columns are standard protein marker (130 kDa), negative control of protein expression, extracted artificial endolysin-ArtE2, partially purified artificial endolysin-ArtE2, and artificial endolysin-ArtE2 after adsorption using nickel-nitrotriacetic acid affinity column chromatography and gradient purification and dialysis using imidazole solution.

[0033] Example 3 Antibacterial effect of artificial endolysin-ArtE2 on Escherichia coli The E. coli cells grown to the logarithmic phase were centrifuged and the supernatant was discarded. The cell pellet was washed twice with buffer and resuspended in HEPES buffer (pH 8.0) to a final concentration of 10 8CFU / mL. Purified artificial endolysin-ArtE2 at different concentrations (2.31μg / mL, 3.97μg / mL and 5.21μg / mL) was added to 50μL of E. coli cell suspension. After incubation at 25°C for 30 minutes, the incubation was diluted, and three replicates were set for each dilution gradient, inoculated on LB agar, and counted using the plate method after incubation at 37°C for 24 hours. HEPES buffer (pH 8.0) was used instead of artificial endolysin-ArtE2 as a control.

[0034] The antimicrobial activity was quantified as [log 10 The relative inactivation level was expressed as (N0 / Ni)], where N0 is the initial number of untreated cells and Ni is the number of residual cells counted after treatment. All data were statistically analyzed. The differences were shown using a t-test at the 5% level. All experiments were repeated at least three times. Error bars represent standard deviations. The results are shown in Figure 5 As shown, when the concentration of artificial endolysin-ArtE2 increased, the number of Escherichia coli decreased significantly; when the concentration increased to 5.21 μg / mL, the concentration of artificial endolysin-ArtE2 was able to completely inhibit the growth of Escherichia coli.

[0035] At the same time, a time-killing test was performed. 8 Artificial endolysin-ArtE2 was added to the suspension of E. coli cells with a final concentration of 5.21 μg / mL. Samples were taken at 0, 5, 10, 15, 20 and 30 minutes after the start of incubation, diluted and inoculated into LB liquid medium, and the OD was measured after 24 hours at 37°C. 600 The treatment with endolysin buffer was used as a control. Figure 6 As shown, 5.21 μg / mL artificial endolysin-ArtE2 treatment for 20 minutes can completely inhibit the growth of Escherichia coli.

[0036] The above test results prove that the artificial endolysin-ArtE2 of the present invention can inhibit the growth of Gram-negative bacteria.

[0037] Example 4 Antibacterial effect of artificial endolysin-ArtE2 on Staphylococcus aureus Staphylococcus aureus grown to logarithmic phase (OD 600 = 0.6) was diluted 100-fold, and 50 μL of the diluted cell suspension (10 8CFU / mL) was mixed with different concentrations (2.31μg / mL, 5.21μg / mL, 6.95μg / mL and 8.11μg / mL) of artificial endolysin-ArtE2, and HEPES-NaOH (pH 7.4) was used as a control. After incubation at 20°C for 30 minutes, the incubation was diluted and treated, and three replicates were set for each dilution gradient. They were inoculated on LB agar and incubated at 37°C overnight. The cell concentration (CFU / mL) was counted and calculated. The experiment was repeated three times.

[0038] At the same time, a time-killing test was performed. 8 Artificial endolysin-ArtE2 with a final concentration of 5.21 μg / mL was added to the suspension of Staphylococcus aureus cells with a CFU / mL. Samples were taken at 0, 5, 10, 15, 20 and 30 minutes after the start of incubation, diluted and inoculated into LB liquid medium, and the OD was measured after 24 hours at 37°C. 600 , Endolysin buffer was added as a control.

[0039] The results are as follows Figure 7 , Figure 8 As shown, the CFU of Staphylococcus aureus was significantly reduced after treatment with artificial endolysin-ArtE2, and the antibacterial effect of artificial endolysin-ArtE2 on Staphylococcus aureus showed concentration dependence, and the lytic activity was significantly improved. The above test results prove that the artificial endolysin-ArtE2 of the present invention can inhibit the growth of Gram-positive bacteria.

[0040] Example 5 Clinical application of artificial endolysin-ArtE2 gel preparation The artificial endolysin-ArtE2 with a content of 5.2 μg / mL was used as the active ingredient, and hydroxyethyl cellulose (1wt%) and polyethylene glycol PEG1500 (1.5wt%) were used as excipients to prepare a gel preparation. The preparation method is as follows: the excipients are first mixed and sterilized at 120°C for 15 minutes, then the artificial endolysin-ArtE2 is dissolved in a 20mM Tris-HCl buffer solution with a pH of 7.5, and finally the solution of the artificial endolysin-ArtE2 is mixed with the excipients in proportion.

[0041] A 54-year-old male developed a Staphylococcus aureus bacterial infection on his finger and applied the above artificial endolysin-ArtE2 preparation to the infected area twice a day. After five days, the lesion was significantly reduced. With continued medication, no bacteria were reported after two weeks ( Fig. 9 ). A skin culture collected was negative for Staphylococcus aureus.

[0042] Although the present invention has been described in detail with reference to the accompanying drawings and in combination with the preferred embodiments, the present invention is not limited thereto. Without departing from the spirit and essence of the present invention, a person of ordinary skill in the art may make various equivalent modifications or substitutions to the embodiments of the present invention, and these modifications or substitutions shall be within the scope of the present invention. Any person of ordinary skill in the art may easily think of changes or substitutions within the technical scope disclosed by the present invention, and these shall be within the scope of protection of the present invention.

Claims

1. An artificial endolysin-ArtE2, characterized in that Its amino acid sequence is: a) a sequence as shown in sequence 1, or, b) a sequence obtained by deleting, replacing or adding one or more amino acid residues of the sequence shown in SEQ ID NO: 1 and retaining the property of controlling pathogenic bacteria infection, or, c) A sequence that has a homology of more than 60% with the amino acid sequence shown in SEQ ID NO: 1 and retains the ability to control pathogenic bacteria infection.

2. A method for preparing the artificial endolysin-ArtE2 as claimed in claim 1, characterized in that: Artificial endolysin-ArtE2 is obtained by recombinant means or chemical synthesis.

3. A pharmaceutical use of the artificial endolysin-ArtE2 as claimed in claim 1, characterized in that: The drug is selected from one of the following: Ⅰ. Drugs that inhibit bacteria; Ⅱ. Drugs for preventing and / or treating diseases caused by bacterial infections; The bacteria are Gram-positive bacteria or Gram-negative bacteria.

4. A biological material related to the artificial endolysin-ArtE2 as claimed in claim 1, characterized in that: Comprising one or more of the following biological materials: (1) A nucleic acid molecule encoding an artificial endolysin-ArtE2; (2) a recombinant expression vector containing the nucleic acid molecule described in (1); (3) a host containing the nucleic acid molecule described in (1); (4) A host containing the recombinant expression vector described in (2).

5. The related biological material according to claim 4, characterized in that: The starting vector of the recombinant expression vector in (2) is pCold I vector.

6. The related biological material according to claim 4, characterized in that The host in (3) or (4) is bacteria, yeast, mammalian cells or plant cells.

7. A pharmaceutical use of the related biological material according to any one of claims 4 to 6, characterized in that: The drug is selected from one of the following: Ⅰ. Drugs that inhibit bacteria; Ⅱ. Drugs for preventing and / or treating diseases caused by bacterial infections; The bacteria are Gram-positive bacteria or Gram-negative bacteria.

8. A preparation, characterized in that The preparation contains the artificial endolysin-ArtE2 as described in claim 1 or the related biological material as described in any one of claims 4 to 6.

9. A pharmaceutical use of the preparation according to claim 8, characterized in that: The drug is selected from one of the following: Ⅰ. Drugs that inhibit bacteria; Ⅱ. Drugs for preventing and / or treating diseases caused by bacterial infections; in, The bacteria are either gram-positive or gram-negative.

Citation Information

Cited By

  • Endolysin and application thereof

    CN117660412A